NCT00946179

Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation

Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intramuscular Route)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 130 (actual)
• Sponsor: Sanofi Pasteur, a Sanofi Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study is in support of the annual application for the variation of the vaccine strains for a marketing authorization. Objectives: * To evaluate the compliance, in terms of immunogenicity, of the influenza vaccine (split virion, inactivated) Northern Hemisphere (NH) 2009-2010 formulation in two adult groups, aged 18 to 60 years and aged 61 years or older. * To describe the safety of the influenza vaccine (split virion, inactivated) NH 2009-2010 formulation in both adult groups.

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	Influenza virus (split virion, inactivated) vaccine	0.5 mL, Intramuscular

Timeline

• Start date: 2009-05-01
• Primary completion: 2009-06-01
• Completion: 2009-07-01
• First posted: 2009-07-24
• Last updated: 2014-01-17

Locations

2 sites across 1 country: Switzerland